Last reviewed 2026-05-28 · How we verify

EDTA Ophthalmic Solution 1.3%

Livionex Inc. · Phase 1 active Small molecule ✓ Verified May 2026

EDTA Ophthalmic Solution 1.3% is a Small molecule drug developed by Livionex Inc.. It is currently in Phase 1 development. Also known as: C-KAD 1.3%.

EDTA Ophthalmic Solution 1.3% is being studied for its safety and efficacy in patients with age-related, low-grade nuclear cataracts. According to ClinicalTrials.gov, the solution is being investigated in a Phase 1/2 clinical trial for its effects on contrast sensitivity in patients with this condition.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	EDTA Ophthalmic Solution 1.3%
Also known as	C-KAD 1.3%
Sponsor	Livionex Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EDTA Ophthalmic Solution 1.3% CI brief — competitive landscape report
EDTA Ophthalmic Solution 1.3% updates RSS · CI watch RSS
Livionex Inc. portfolio CI

Frequently asked questions about EDTA Ophthalmic Solution 1.3%

What is EDTA Ophthalmic Solution 1.3%?

EDTA Ophthalmic Solution 1.3% is a Small molecule drug developed by Livionex Inc..

Who makes EDTA Ophthalmic Solution 1.3%?

EDTA Ophthalmic Solution 1.3% is developed by Livionex Inc. (see full Livionex Inc. pipeline at /company/livionex-inc).

Is EDTA Ophthalmic Solution 1.3% also known as anything else?

EDTA Ophthalmic Solution 1.3% is also known as C-KAD 1.3%.

What development phase is EDTA Ophthalmic Solution 1.3% in?

EDTA Ophthalmic Solution 1.3% is in Phase 1.

Manufacturer: Livionex Inc. — full pipeline
Also known as: C-KAD 1.3%

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing